Don't want to miss the best from Business Standard?
Pfizer has announced that it has entered into a marketing and supply agreement with Mylan Pharmaceuticals for the marketing and sale of two of its brands, Ativan and Pacitane.
The agreement is for a period of five years and applies within the territory of India.Mylan has a strong presence in the Central Nervous System (CNS) therapy area, supported by skilled resources that engage with super specialists such as neurologists and psychiatrists. This collaboration with Mylan will enhance the distribution and in-clinic presence of Pfizers products.
Pfizer is involved in the manufacturing, marketing, trading, and export of pharmaceutical products.
The pharma company's net profit rose 2.8% to Rs 127.60 crore in Q3 FY25 as against Rs 124.11 crore recorded in Q3 FY24. Revenue from operations shed 0.4% year on year to Rs 537.99 crore during the quarter.
Shares of Pfizer shed 0.41% to Rs 4,095.55 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app